Where the 5%-at-16-weeks marker comes from
The STEP-1 trial (Wilding et al., NEJM 384:989-1002, 2021) enrolled 1961 adults with BMI ≥30 (or ≥27 + comorbidity) and randomized 2:1 to semaglutide 2.4 mg or placebo, both with lifestyle intervention. Titration ran weeks 0-16 (0.25 → 2.4 mg); maintenance ran weeks 17-68.
Analysts noticed a strong pattern in the STEP-1 data: patients who lost ≥5% of body weight by week 16 (the first week at maintenance dose) were overwhelmingly the same patients who hit the trial mean (14.9%) at week 68. This 16-week marker has been used by obesity-medicine specialists since the trial published.
The AACE 2024 obesity consensus statement formalized this as clinical guidance: at each 3-month follow-up, weight-loss trajectory should be assessed against the 5% marker. Patients not on trajectory should have their treatment modified — extended titration, faster escalation, drug switch, or workup for a missed diagnosis.
- Sources for this section
- Wilding JPH et al. — Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP-1) — New England Journal of Medicine, 384:989-1002, 2021
- AACE 2024 Obesity Consensus Statement — Endocrine Practice
The response quartiles — where you likely sit
STEP-1 published detailed response distributions. Reading these tells you what "working" actually looks like.
≥5% loss: 86% of the semaglutide arm hit it. If you are in this bucket by week 16, you are a responder.
≥10% loss: 69% hit it. This is the most common outcome band.
≥15% loss: 51% hit it. Roughly half the trial cohort ended up here or above.
≥20% loss: 32%. Roughly one-third — the upper responder band.
What predicts landing in the higher bands: hitting the 5% marker at week 16 with margin (7-9%), staying on the dose schedule, protein 0.7-1.0 g/lb goal weight, strength training 2×/week, sleep 7+ hours. What predicts the lower bands: near-miss at week 16 (4%), adherence gaps, no strength training.
What each week should look like if it is working
Weeks 1-4 (0.25 mg): 1-2% of body weight lost. Slower than expected. Normal.
Weeks 4-8 (0.5 mg): 3-4% total. First meaningful appetite suppression. Clothing starts feeling different.
Weeks 8-12 (1.0 mg): 4-6% total. Peak GI side-effect window per STEP-1. If nausea is your worst here, you are on-schedule.
Weeks 12-16 (1.7 mg): 6-8% total. Approach the 5% marker with margin. If you are stuck at 3-4% here, prescriber conversation is due.
Week 16 (2.4 mg maintenance starts): if you are ≥5% down, continue on-schedule. If you are below 5%, this is the decision-tree fork below.
If you miss the 5% marker — the decision tree
Roughly 14% of STEP-1 patients did not hit 5% by week 16. If you are one of them, here is the evidence-based decision tree — take it to your prescriber, do not act unilaterally.
1. Rule out adherence. Missed weekly doses, or stretching to every 10 days, drops steady-state exposure below therapeutic. Honest self-audit first — if adherence is the issue, fix it and re-check at week 20.
2. Rule out a missed diagnosis. Hypothyroidism (check TSH), obstructive sleep apnea (STOP-BANG questionnaire → sleep study), and elevated cortisol (Cushing screen) all blunt GLP-1 response. AACE 2024 recommends a workup for non-responders.
3. Consider extended titration or dose delay. Some patients respond at 1.7 mg but not at 2.4 mg — a "sub-maintenance" strategy that is off-label but observed. Requires prescriber judgment; STEP-5 did not test this formally.
4. Consider drug switch. Tirzepatide (Zepbound) achieved −20.9% in SURMOUNT-1 vs semaglutide −14.9% in STEP-1 — the dual GIP/GLP-1 agonism produces larger loss on average. Non-responders to semaglutide often respond to tirzepatide (SURPASS-2 head-to-head trial confirmed the direction in diabetes; obesity extrapolation is reasonable but not proven).
- Sources for this section
- Jastreboff AM et al. — Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1) — New England Journal of Medicine, 387:205-216, 2022
Non-scale markers — what else "working" looks like
The scale is not the only signal. STEP-1 secondary endpoints included several patient-relevant markers that often improve before big scale changes:
Waist circumference: STEP-1 arm lost ~13 cm on average. Tape measure once weekly at the level of the belly button is more sensitive than the scale to fat vs water changes.
HbA1c: Both diabetic and pre-diabetic patients see meaningful drops (0.5-1.5%) within 12 weeks even before large weight loss.
Blood pressure: STEP-1 showed 4-6 mmHg systolic drop. If your BP is coming down at week 8-12 but the scale is stubborn, the drug is working — the body composition change is ahead of scale weight.
Sleep apnea: SURMOUNT-OSA (Malhotra et al., NEJM 2024) established tirzepatide-driven AHI reductions of 25-30 events/hour in adults with obesity + moderate/severe OSA. If you snore or use CPAP, your sleep improvement is a real marker.
Food-noise quieting: subjective but real. Patients who describe "forgetting to eat" or "meals feeling like a chore" are responding at the brain-reward-circuit level even when the scale is slow.
- Sources for this section
- Malhotra A et al. — Tirzepatide for the Treatment of Obstructive Sleep Apnea (SURMOUNT-OSA) — New England Journal of Medicine, 391:1193-1205, 2024
Weigh daily, average weekly — the trend that matters
Once-weekly weigh-ins hide the trend. Water fluctuation is ±1-3% of body weight day-to-day (sodium, carbohydrate load, menstrual cycle, exercise glycogen). A once-weekly measurement can land on a peak or valley and mislead you.
The evidence-based method: weigh at the same time every morning (post-void, pre-eating), record it, and compute a 7-day rolling average. The rolling average is the trend. STEP-1 recorded weight at each in-clinic visit — the 7-day average is a close proxy for that.
What to look for: a rolling-average drop of ~0.2-0.4% of body weight per week from week 4 to week 16, then ~0.15-0.3% per week from week 16 to week 44, tapering after. If your rolling average is flat for 3+ weeks, that is a plateau to investigate; a flat one-morning reading is not.
Frequently asked questions
- What if I lose exactly 5% at week 16 — am I on the low end?
- You are right at the boundary. STEP-1 patients who hit ≥5% by week 16 were mostly responders, but hitting the marker with margin (7-9%) correlates with landing in the higher final quartiles. Talk to your prescriber about protein target and strength training if you are at the boundary — small adherence changes now shift the final quartile you end up in.
- Can I switch to Zepbound if Wegovy is not working?
- Yes — this is a common step. SURMOUNT-1 mean loss (−20.9%) exceeds STEP-1 mean (−14.9%) by ~40%. Insurance coverage is the practical barrier (see /research/pbm-formulary-glp1-teardown for the PBM landscape). Some patients need to fail Wegovy in step-therapy documentation before Zepbound is approved.
- Why does STEP-1 use week 16 and not week 12?
- Week 16 is the first week on the maintenance dose (2.4 mg). Any check earlier is measuring loss during titration when the dose is still sub-therapeutic. The 5% marker is defined at the first meaningful check-in on the therapeutic dose.
- Is 5% at 16 weeks the same rule for Zepbound?
- Yes, with a higher target if anything. SURMOUNT-1 patients on tirzepatide reached ~5-8% loss by week 16, so ≥5% is still the minimum acceptable trajectory. AACE 2024 uses the same 5% threshold across all approved obesity medications.
- What if I plateau after hitting 8% at week 16?
- Plateaus 2-4 weeks long are common between week 20 and week 60 in STEP-1 and did not require intervention in the trial cohort. Run through the checklist — protein 0.7 g/lb goal weight, strength training 2x/week, sleep 7+ hours, adherence to weekly dose. If all four are yes and the plateau is under 4 weeks, wait it out.
Disclosure: Glpverdict is affiliate-funded but editorially independent. Some links above are sponsored — we earn commission on signups with a partner provider. This does not affect our editorial rankings or medical review.
